Category: Life Sciences

AWS Genomics has released a new whitepaper, Genomics Data Transfer, Analytics, and Machine Learning using AWS Services, that provides essential information and guidance on how to build a Next Generation Sequencing (NGS) platform using AWS services, from instrument to interpretation. Accompanying the new whitepaper are three solutions, developed based on feedback from AWS life science […]

AWS re:Invent routinely fills several Las Vegas venues with standing-room only crowds, but we are bringing it to you with an all-virtual and free event this year. This year’s conference is gearing up to be our biggest yet and we have an exciting program planned with five keynotes, 18 leadership sessions, and over 500 breakout […]

Guest authored by Bryan Lajoie, Staff Bioinformatics Scientist at Illumina Inc. — We are pleased to announce the release of a comprehensive reanalysis of 3,202 deeply-sequenced samples from the 1000 Genomes Project(1kGP) using the Illumina DRAGEN (Dynamic Read Analysis for GENomics) Bio-IT platform. This seminal dataset will be freely available for researchers across the world to use […]

The latest release of Cromwell (v52) includes a number of major changes and improvements to the AWS Batch backend for Cromwell. Among the numerous changes, we have enabled Cromwell’s Call Caching feature when using AWS Batch with files in Amazon Simple Storage Service (Amazon S3). This allows genomics researchers to efficiently develop and run workflows […]

Introduction Bio-pharmaceutical companies have always had a responsibility to report adverse events (AE), whether in clinical development or post market-approval scenarios, to the Food and Drug Administration (FDA).  The COVID-19 pandemic and the race to find effective treatments for this disease has caused both the FDA and bio-pharmaceutical organizations around the world to re-imagine the […]

In this blog post, we describe the first step of a process for qualifying AWS services for use as part of GxP workloads, sometimes referred to in the industry as “whitelisting” services. AWS customers with GxP compliance requirements might want to control access to the AWS services their developers use. During the supplier assessment of […]

Co-authored by Grace Tiao, Associate Director of Computational Genomics at the Broad Institute and Erin Chu, DVM, Ph.D., Life Sciences Lead, AWS Open Data Program Today we announce that data from the Genome Aggregation Consortium (gnomAD) is available for the first time on Amazon Web Services (AWS) as part of the Registry of Open Data […]

Life Science companies are witnessing substantial growth in number of Adverse Events (AE) being reported for their products. This may be due to the increase in data volumes coming from journals, articles, social media, and non-standardized data sources. Evolving regulations and increasing pressure to improve quality and patient safety, while maintaining patient privacy rights, and […]

Introduction Bringing a new drug to market is a slow and laborious process. According to Tufts Centre for the Study of Drug Development, it takes on average between 7 to 10 years and costs more than $2.5 billion to bring a new drug to market. (1) More than half of this time and capital is […]

Good practice (GxP) guidelines were established by the Food and Drug Administration (FDA) and aim to ensure organizations working in life sciences develop, manufacture, and distribute products that are safe, meet quality guidelines, and are fit for use. GxP compliance has been a part of the life sciences industry for many years and heavily influences […]